CLINICAL_TRIALS ClinicalTrials.gov record update

A Platform Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT06445062
Title field or adapter rule: {'original_value': 'A Platform Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors', 'source_field': 'protocolSection.identificationModule.officialTitle'}
Ingested At: 2026-10-31T23:27:25.244581+00:00
Published At: 2026-09-22T00:00:00+00:00
Record Updated At: 2026-09-22
Source Retrieved At: 2026-10-31T22:17:56.788771+00:00
Timestamp Basis: ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter
Date limitation: ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions: ["Colorectal Cancer", "CRC", "Pancreatic Ductal Adenocarcinoma", "PDAC", "Gastrointestinal Cancer", "Metastatic Pancreatic Ductal Adenocarcinoma"]
protocolSection.statusModule.lastUpdatePostDateStruct: {"date": "2026-09-22", "type": "ACTUAL"}
protocolSection.identificationModule.nctId: "NCT06445062"
protocolSection.identificationModule.officialTitle: "A Platform Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors"
protocolSection.statusModule.overallStatus: "RECRUITING"
protocolSection.designModule.phases: ["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct: null

Study condition terms

Interventions recorded in this study

{'armGroupLabels': ['Subprotocol A: RAS-mutated unresectable or metastatic CRC or metastatic PDAC', 'Subprotocol B: RAS-mutated unresectable or metastatic CRC or metastatic PDAC', 'Subprotocol C: metastatic PDAC', 'Subprotocol D: RAS G12D-mutated unresectable or metastatic CRC or metastatic PDAC', 'Subprotocol E: RAS G12D-mutated unresectable or metastatic CRC or metastatic PDAC', 'Subprotocol F: RAS G12D-mutated metastatic PDAC'], 'description': 'Oral tablet', 'name': 'RMC-6236', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['Subprotocol A: RAS-mutated unresectable or metastatic CRC or metastatic PDAC', 'Subprotocol B: RAS-mutated unresectable or metastatic CRC or metastatic PDAC', 'Subprotocol D: RAS G12D-mutated unresectable or metastatic CRC or metastatic PDAC', 'Subprotocol E: RAS G12D-mutated unresectable or metastatic CRC or metastatic PDAC'], 'description': 'IV infusion', 'name': 'mFOLFOX6 regimen', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['Subprotocol A: RAS-mutated unresectable or metastatic CRC or metastatic PDAC', 'Subprotocol D: RAS G12D-mutated unresectable or metastatic CRC or metastatic PDAC'], 'description': 'IV infusion', 'name': 'bevacizumab', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['Subprotocol A: RAS-mutated unresectable or metastatic CRC or metastatic PDAC', 'Subprotocol D: RAS G12D-mutated unresectable or metastatic CRC or metastatic PDAC'], 'description': 'IV infusion', 'name': 'mFOLFIRINOX regimen', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['Subprotocol B: RAS-mutated unresectable or metastatic CRC or metastatic PDAC', 'Subprotocol E: RAS G12D-mutated unresectable or metastatic CRC or metastatic PDAC', 'Subprotocol G: RAS G12D-mutated metastatic CRC'], 'description': 'IV infusion', 'name': 'cetuximab', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['Subprotocol C: metastatic PDAC', 'Subprotocol F: RAS G12D-mutated metastatic PDAC'], 'description': 'IV infusion', 'name': 'gemcitabine', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['Subprotocol C: metastatic PDAC', 'Subprotocol F: RAS G12D-mutated metastatic PDAC'], 'description': 'IV infusion', 'name': 'nab-paclitaxel', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['Subprotocol D: RAS G12D-mutated unresectable or metastatic CRC or metastatic PDAC', 'Subprotocol E: RAS G12D-mutated unresectable or metastatic CRC or metastatic PDAC', 'Subprotocol F: RAS G12D-mutated metastatic PDAC', 'Subprotocol G: RAS G12D-mutated metastatic CRC'], 'description': 'Oral Tablet', 'name': 'RMC-9805', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['Subprotocol G: RAS G12D-mutated metastatic CRC'], 'description': 'IV infusion', 'name': 'FOLFIRI regimen', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

Drug names recorded in this source

A recorded drug name is not by itself an indication or a condition-specific relationship.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.